TRON GROUP INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6 USD | -1.32% |
|
-.--% | -1.32% |
| 2022 | TRON Group Inc. Appoints James D. Talton as President, Secretary/Treasurer and Director | CI |
| 2022 | TRON Group Inc. Appoints James D. Talton as Chief Executive Officer | CI |
| Sales 2016 | 1.48M 118M | Sales 2017 | 1.48M 118M | Capitalization | 104M 8.32B |
|---|---|---|---|---|---|
| Net income 2016 | - 0 | Net income 2017 | - 0 | EV / Sales 2016 * | - |
| Net cash position 2016 * | - 0 | Net cash position 2017 * | - 0 | EV / Sales 2017 * | - |
| P/E ratio 2016 * |
-
| P/E ratio 2017 * |
-
| Employees | - |
| Yield 2016 * |
-
| Yield 2017 * |
-
| Free-Float | 1.16% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.32% | ||
| 3 months | -1.32% | ||
| 6 months | -1.32% | ||
| Current year | -1.32% |
Current year
0.60
0.60
1 year
0.320.85
3 years
0.253.90
5 years
0.097.00
10 years
0.097.00
| Managers | Title | Age | Since |
|---|---|---|---|
Quoc Tuan Nguyen
CEO | Chief Executive Officer | - | - |
| Director/Board Member | 46 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 46 | - | |
Quoc Tuan Nguyen
CEO | Chief Executive Officer | - | - |
Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company. The Company is developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The Company is developing a clinical pipeline of oral, topical and injectable small molecule drug candidates to treat human cancer, central nervous system (CNS) disorders and infectious diseases. The pipeline includes 10 clinical-stage proprietary and partnered programs including Triapine, Ammonium Tetrathiomolybdate and Aza-TdC, targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3, targeting CNS; and Ramoplanin and NanoDOX, targeting infectious disease. Leveraging its expertise in nanoparticle and fine-particle formulations, the Company is focused on formulation development aimed at improving drug absorption and stability. Triapine is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.32% | 104M | |
| -2.67% | 103B | |
| +1.80% | 95.28B | |
| +1.46% | 22.15B | |
| -15.56% | 21.02B | |
| -8.58% | 18.15B | |
| -41.01% | 16.73B | |
| -13.27% | 16.05B | |
| +4.61% | 13.68B | |
| +34.95% | 12.17B |
- Stock Market
- Equities
- TGRP Stock
